It may not be a sustainable business with current business models. But if cures came with a "post-scription" model where the cured patient paid, say, 0.5% - 1% of their income to the drug company in perpetuity, then incentives are aligned. (Of course, administration is a problem here.) As someone with an incurable disease, I would happily pay for a cure in such a way...